奥拉西坦对重型颅脑损伤的影响

Effectiveness of oxiracetam in patients with severe craniocerebral injury

目的探讨奥拉西坦对重型颅脑损伤患者的影响。方法2016年12月至2018年12月,连续性收集重型颅脑损伤患者100例,将患者随机分为观察组和对照组,各50例。2组均给予常规治疗,观察组在此基础上给予奥拉西坦4 g,iv gtt,qd,总疗程为12周。治疗结束后观察2组神经功能、认知功能、生活质量和不良反应等。结果治疗后,观察组NIHSS评分显著低于对照组(14.25±3.44 vs 16.87±3.43,P<0.01),MMSE评分显著高于对照组(24.65±2.52 vs 22.61±2.26,P<0.01),健康相关的生存质量(SF-36)高于对照组(65.71±12.72 vs 61.84±13.77,P<0.05),IL-6和TNF-α水平均较对照组降低[(17.75±9.74)ng·L^-1vs(21.84±9.65)ng·L^-1,P<0.05;(18.58±5.61)ng·L^-1vs(20.92±5.23)ng·L^-1,P<0.05)]。2组患者不良反应发生率相当,差异无统计学意义(P>0.05)。结论奥拉西坦可改善重型颅脑损伤患者神经功能和认知功能,提高生活质量,无明显不良反应,值得推广。

AIM To investigate the efficacy of oxiracetam in the treatment of severe craniocerebral injury.METHODS From December 2016 to December 2018,100 patients with severe craniocerebral injury were collect-ed.They were randomly divided into observation group and control group with 50 patients in each group.Both groups were given routine treatment.The observation group was given oxiracetam 4 g,iv gtt,qd,for 12 weeks.Af-ter treatment,the neurological function,cognitive function,quality of life and adverse drug reactions of the 2 groups were observed.RESULTS After treatment,the NIHSS score of the observation group was lower than that of the control group(14.25±3.44 vs 16.87±3.43,P<0.01);the MMSE score of the observation group was significantly higher than that of the control group(24.65±2.52 vs 22.61±2.26,P<0.01);the health-relat-ed quality of life(SF-36)in the observation group was higher than that in the control group(65.71±12.72 vs 61.84±13.77,P<0.05).The levels of IL-6 and TNF-αin the observation group were lower than those in the control group[(17.75±9.74 vs 21.84±9.65 ng·L^-1,P<0.05)and(18.58±5.61 vs 20.92±5.23 ng·L^-1,P<0.05)].There was no significant difference in adverse drug reactions between the 2 groups(P>0.05).CONCLUSION Oxiracetam can improve the neurological and cognitive functions of patients with severe craniocere-bral injury,improve the quality of life,with no obvious adverse drug reactions,and is worthy of promotion.